Phase 1 Clinical Trial

Ad-Mediated IL-2 Gene Therapy Deemed Safe in Cancer Pts

Published in Gene Therapy Weekly, April 19th, 1999

Adenovector-mediated delivery of the interleukin-2 (IL-2) gene into metastatic breast cancer and melanoma patients demonstrated the safety of adenovirus-mediated gene therapy in humans.

A.K. Stewart and colleagues from several institutions in Canada and the United States conducted a phase 1 trial of direct injection of an E1,E3-deleted adenovirus encoding IL-2 (AdCAIL-2) into subcutaneous deposits of melanoma or breast cancer ("Adenovector-Mediated Gene Delivery of Interleukin-2 in Metastatic Breast Cancer and Melanoma: Results of a Phase 1 Clinical Trial," Gene Therapy, March 1999;6(3):350-63).

"To begin to explore the utility and safety of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1999-04-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry